Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
OTCPK:TEVJF's Cash to Debt is ranked lower than
51% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.07 vs. OTCPK:TEVJF: 0.22 )
OTCPK:TEVJF' s 10-Year Cash to Debt Range
Min: 0.08   Max: 1.03
Current: 0.22

0.08
1.03
Equity to Asset 0.50
OTCPK:TEVJF's Equity to Asset is ranked higher than
61% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. OTCPK:TEVJF: 0.50 )
OTCPK:TEVJF' s 10-Year Equity to Asset Range
Min: 0.4   Max: 0.59
Current: 0.5

0.4
0.59
Interest Coverage 13.17
OTCPK:TEVJF's Interest Coverage is ranked higher than
55% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 236.52 vs. OTCPK:TEVJF: 13.17 )
OTCPK:TEVJF' s 10-Year Interest Coverage Range
Min: 3.6   Max: 328.25
Current: 13.17

3.6
328.25
F-Score: 8
Z-Score: 2.65
M-Score: -2.70
WACC vs ROIC
4.93%
10.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.49
OTCPK:TEVJF's Operating margin (%) is ranked higher than
90% of the 1104 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.08 vs. OTCPK:TEVJF: 19.49 )
OTCPK:TEVJF' s 10-Year Operating margin (%) Range
Min: 8.12   Max: 26.78
Current: 19.49

8.12
26.78
Net-margin (%) 15.07
OTCPK:TEVJF's Net-margin (%) is ranked higher than
89% of the 1104 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.42 vs. OTCPK:TEVJF: 15.07 )
OTCPK:TEVJF' s 10-Year Net-margin (%) Range
Min: 5.73   Max: 21.09
Current: 15.07

5.73
21.09
ROE (%) 13.17
OTCPK:TEVJF's ROE (%) is ranked higher than
82% of the 1133 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. OTCPK:TEVJF: 13.17 )
OTCPK:TEVJF' s 10-Year ROE (%) Range
Min: 4.23   Max: 27
Current: 13.17

4.23
27
ROA (%) 6.52
OTCPK:TEVJF's ROA (%) is ranked higher than
79% of the 1166 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. OTCPK:TEVJF: 6.52 )
OTCPK:TEVJF' s 10-Year ROA (%) Range
Min: 2.26   Max: 13.11
Current: 6.52

2.26
13.11
ROC (Joel Greenblatt) (%) 43.55
OTCPK:TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.41 vs. OTCPK:TEVJF: 43.55 )
OTCPK:TEVJF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 12.89   Max: 49.79
Current: 43.55

12.89
49.79
Revenue Growth (3Y)(%) 4.80
OTCPK:TEVJF's Revenue Growth (3Y)(%) is ranked higher than
70% of the 941 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. OTCPK:TEVJF: 4.80 )
OTCPK:TEVJF' s 10-Year Revenue Growth (3Y)(%) Range
Min: 4.8   Max: 23.4
Current: 4.8

4.8
23.4
EBITDA Growth (3Y)(%) 10.00
OTCPK:TEVJF's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 840 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. OTCPK:TEVJF: 10.00 )
OTCPK:TEVJF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.4   Max: 47.2
Current: 10

-10.4
47.2
EPS Growth (3Y)(%) 4.80
OTCPK:TEVJF's EPS Growth (3Y)(%) is ranked higher than
74% of the 818 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. OTCPK:TEVJF: 4.80 )
OTCPK:TEVJF' s 10-Year EPS Growth (3Y)(%) Range
Min: -25.6   Max: 69.8
Current: 4.8

-25.6
69.8
» OTCPK:TEVJF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OTCPK:TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.60
TEVJF's P/E(ttm) is ranked higher than
90% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 59.80 vs. TEVJF: 18.60 )
TEVJF' s 10-Year P/E(ttm) Range
Min: 10.53   Max: 1072.29
Current: 18.6

10.53
1072.29
Forward P/E 12.08
TEVJF's Forward P/E is ranked higher than
95% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TEVJF: 12.08 )
N/A
PE(NRI) 18.50
TEVJF's PE(NRI) is ranked higher than
91% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 56.20 vs. TEVJF: 18.50 )
TEVJF' s 10-Year PE(NRI) Range
Min: 10.53   Max: 938.25
Current: 18.5

10.53
938.25
P/B 2.40
TEVJF's P/B is ranked higher than
78% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. TEVJF: 2.40 )
TEVJF' s 10-Year P/B Range
Min: 1.37   Max: 4.88
Current: 2.4

1.37
4.88
P/S 2.63
TEVJF's P/S is ranked higher than
73% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.25 vs. TEVJF: 2.63 )
TEVJF' s 10-Year P/S Range
Min: 1.58   Max: 5.86
Current: 2.63

1.58
5.86
PFCF 17.20
TEVJF's PFCF is ranked higher than
93% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TEVJF: 17.20 )
TEVJF' s 10-Year PFCF Range
Min: 8.45   Max: 39.85
Current: 17.2

8.45
39.85
POCF 11.08
TEVJF's POCF is ranked higher than
93% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.64 vs. TEVJF: 11.08 )
TEVJF' s 10-Year POCF Range
Min: 6.56   Max: 26.77
Current: 11.08

6.56
26.77
EV-to-EBIT 15.42
TEVJF's EV-to-EBIT is ranked higher than
88% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.16 vs. TEVJF: 15.42 )
TEVJF' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 991
Current: 15.42

11.7
991
PEG 3.85
TEVJF's PEG is ranked higher than
89% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TEVJF: 3.85 )
TEVJF' s 10-Year PEG Range
Min: 0.35   Max: 174.07
Current: 3.85

0.35
174.07
Shiller P/E 23.40
TEVJF's Shiller P/E is ranked higher than
91% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TEVJF: 23.40 )
TEVJF' s 10-Year Shiller P/E Range
Min: 14.13   Max: 75
Current: 23.4

14.13
75
Current Ratio 1.17
TEVJF's Current Ratio is ranked higher than
53% of the 1023 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. TEVJF: 1.17 )
TEVJF' s 10-Year Current Ratio Range
Min: 1.06   Max: 2.95
Current: 1.17

1.06
2.95
Quick Ratio 0.82
TEVJF's Quick Ratio is ranked higher than
51% of the 1023 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. TEVJF: 0.82 )
TEVJF' s 10-Year Quick Ratio Range
Min: 0.69   Max: 2.18
Current: 0.82

0.69
2.18
Days Inventory 189.56
TEVJF's Days Inventory is ranked higher than
62% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 139.62 vs. TEVJF: 189.56 )
TEVJF' s 10-Year Days Inventory Range
Min: 131.65   Max: 208.14
Current: 189.56

131.65
208.14
Days Sales Outstanding 97.37
TEVJF's Days Sales Outstanding is ranked higher than
69% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.57 vs. TEVJF: 97.37 )
TEVJF' s 10-Year Days Sales Outstanding Range
Min: 95.91   Max: 153.21
Current: 97.37

95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.13
TEVJF's Dividend Yield is ranked higher than
75% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.30 vs. TEVJF: 2.13 )
TEVJF' s 10-Year Dividend Yield Range
Min: 0.2   Max: 3.26
Current: 2.13

0.2
3.26
Dividend Payout 0.38
TEVJF's Dividend Payout is ranked higher than
98% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TEVJF: 0.38 )
TEVJF' s 10-Year Dividend Payout Range
Min: 0.05   Max: 0.86
Current: 0.38

0.05
0.86
Dividend growth (3y) 15.30
TEVJF's Dividend growth (3y) is ranked higher than
86% of the 479 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. TEVJF: 15.30 )
TEVJF' s 10-Year Dividend growth (3y) Range
Min: -6.7   Max: 80.9
Current: 15.3

-6.7
80.9
Yield on cost (5-Year) 5.96
TEVJF's Yield on cost (5-Year) is ranked higher than
94% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. TEVJF: 5.96 )
TEVJF' s 10-Year Yield on cost (5-Year) Range
Min: 0.57   Max: 9.25
Current: 5.96

0.57
9.25
Share Buyback Rate 1.30
TEVJF's Share Buyback Rate is ranked higher than
93% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.10 vs. TEVJF: 1.30 )
TEVJF' s 10-Year Share Buyback Rate Range
Min: 2.6   Max: -10.9
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.10
TEVJF's Price/DCF (Projected) is ranked higher than
96% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TEVJF: 1.10 )
TEVJF' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 7.38
Current: 1.1

0.6
7.38
Price/Median PS Value 0.90
TEVJF's Price/Median PS Value is ranked higher than
94% of the 1277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. TEVJF: 0.90 )
TEVJF' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 1.71
Current: 0.9

0.49
1.71
Earnings Yield (Greenblatt) 6.50
TEVJF's Earnings Yield (Greenblatt) is ranked higher than
85% of the 1150 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TEVJF: 6.50 )
TEVJF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 8.6
Current: 6.5

0.1
8.6
Forward Rate of Return (Yacktman) -2.15
TEVJF's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 582 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. TEVJF: -2.15 )
TEVJF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.2   Max: 51.2
Current: -2.15

-2.2
51.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TEVA.USA, TEV.Germany, TEVA.Israel, TEVA.Switzerland,
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").
» More Articles for TEVJF

Headlines

Articles On GuruFocus.com
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Analysts Weigh in on Auspex Pharmaceuticals Following Teva Acquisition Mar 31 2015 
Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 
Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI Dec 08 2014 
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Why Opko Health Is a Better Investment Than Apple Dec 02 2014 
The Gurus’ Favorite Asian Stocks Sep 07 2014 

More From Other Websites
Teva Can Preserve $5-a-Share Earnings Goal With Mylan: Real M&A Apr 17 2015
Mylan dismisses takeover interest from Teva Pharmaceuticals Apr 17 2015
Mylan skeptical of rumored Teva bid; hasn't received offer Apr 17 2015
Mylan skeptical of rumored Teva bid; hasn't received offer Apr 17 2015
Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog Apr 17 2015
Teva & Mylan: Deal or No Deal? Apr 17 2015
Teva Getting Serious About Mylan Bid, Says Report Apr 17 2015
Mylan Says It Is Opposed To Possible Teva Pharmaceuticals Merger Apr 17 2015
Teva Is Exploring Mylan Bid to Create Generic-Drug Giant Apr 17 2015
Teva Pharmaceuticals (TEVA) Stock Gains Today on Mylan Takeover Talk Apr 17 2015
Mylan (MYL) Stock Spikes in Afternoon Trading on Teva Takeover Speculation Apr 17 2015
Mylan says merger with Teva would be bad fit Apr 17 2015
Mylan to Teva: Thanks but no thanks, we'll stay independent Apr 17 2015
Teva Is Said to Explore Takeover Offer for Mylan Apr 17 2015
Teva Is Said to Explore Mylan Bid to Create Generic-Drug Giant Apr 17 2015
FDA approves generic version of top-selling MS drug Copaxone Apr 17 2015
FDA approves generic version of top-selling MS drug Copaxone Apr 17 2015
Weight Watchers (WTW)’ Horrid Q1 Not Enough to Stop North Tide Capital From Double Digit Returns Apr 17 2015
FDA Approves Generic Copaxone, but When Will it Become Available? Apr 16 2015
VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog Apr 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK